Table 5a, 5b.
ORs and 95%CIs for pancreatic cancer related to type 2 diabetes stratified by metformin exposure in a San Francisco clinic-based case-control study of pancreatic cancer
| Diabetes | Metformin Use | Cases/Controls | OR1 (95% CI) |
|---|---|---|---|
| No | --- | 455/780 | 1.00 (ref) |
| Yes | No | 28/29 | 1.44 (0.78–2.67) |
| Yes | Yes | 53/60 | 1.19 (0.72–1.99) |
| Table 5b
| ||||||
|---|---|---|---|---|---|---|
| No Metformin N = 28/29 |
Metformin Use ≤5 years N = 32/30 |
Metformin Use >5 years N = 18/28 |
||||
| Diabetes Duration | N | OR1 (95% CI) | N | OR1 (95% CI) | N | OR1 (95% CI) |
| None2 | 1.00 | 1.00 | 1.00 | |||
| 1–5 years | 16/12 | 2.12 (0.89–5.02) | 23/11 | 2.77 (1.26–6.09) | -- | |
| 5–10 years | 7/6 | 1.12 (0.29–4.35) | 8/13 | 0.58 (0.20–1.69) | */* | 1.06 (0.23–4.88) |
| >10 years | */* | 0.36 (0.09–1.39) | */* | 0.09 (0.01–1.26) | 14/22 | 0.84 (0.32–2.25) |
1
Adjusted for age, sex, race, BMI, history of pancreatitis, alcohol, smoking, family history of PC, diabetes medications. ORs for diabetes with metformin use and diabetes without metformin use are not significantly different (p=0.57).
1
Adjusted for age, sex, race, BMI, history of pancreatitis, alcohol, smoking, family history of PC, diabetes drugs.
2
Referent group is non-diabetics (n=1235).
*
Sample sizes of groups with ≤5 cases or controls are redacted to preserve anonymity.